Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 495-506

  Tzvetkov, Mladen Vassilev ^a   Brockmöller, Jürgen ^a   Roots, Ivar ^b   Kirchheiner, Julia ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Antidepressant treatment; Haplotype; Major depression; SNP; TPH2

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; MIRTAZAPINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE 2; VENLAFAXINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRYPTOPHAN HYDROXYLASE 2 GENE;

ANTIDEPRESSIVE AGENTS; BASE SEQUENCE; BRAIN; DEPRESSIVE DISORDER, MAJOR; DNA PRIMERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HAPLOTYPES; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRYPTOPHAN HYDROXYLASE; VARIATION (GENETICS);

EID: 44449124504     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fb02cb     Document Type: Article

References (58)

1. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299:76.
2. Zill P, Buttner A, Eisenmenger W, Bondy B, Ackenheil M. Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains. Eur Neuropsychopharmacol 2004; 14:282-284.
3. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004; 305:217.
4. Zill P, Baghai TC, Zwanzger P, Schule C, Eser D, Rupprecht R, et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004; 9:1030-1036.
5. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry 2004; 56:581-586.
6. Harvey M, Shink E, Tremblay M, Gagne B, Raymond C, Labbe M, et al. Support for the involvement of TPH2 gene in affective disorders. Mol Psychiatry 2004; 9:980-981.
7. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ. Nested Association Between Genetic Variation in Tryptophan Hydroxylase II, Bipolar Affective Disorder, and Suicide Attempts. Biol Psychiatry 2007; 61:181-186.
8. Van Den Bogaert A, Sleegers K, De Zutter S, Heyrman L, Norrback KF, Adolfsson R, et al. Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. Arch Gen Psychiatry 2006; 63:1103-1110.
9. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, et al. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 2005; 62:1109-1118.
10. Mossner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2006; 9:437-442.
11. Sheehan K, Lowe N, Kirley A, Mullins C, Fitzgerald M, Gill M, et al. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 2005; 10:944-949.
12. Walitza S, Renner TJ, Dempfle A, Konrad K, Wewetzer C, Halbach A, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 2005; 10:1126-1132.
13. De Luca V, Hlousek D, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses. Genes Brain Behav 2006; 5:107-110.
14. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berlin) 2005; 183:378-382.
15. De Luca V, Mueller DJ, Tharmalingam S, King N, Kennedy JL. Analysis of the novel TPH2 gene in bipolar disorder and suicidality. Mol Psychiatry 2004; 9:896-897.
16. De Luca V, Voineskos D, Wong GW, Shinkai T, Rothe C, Strauss J, et al. Promoter polymorphism of second tryptophan hydroxylase isoform (TPH2) in schizophrenia and suicidality. Psychiatry Res 2005; 134:195-198.
17. Dahl JP, Cubells JF, Ray R, Weller AE, Lohoff FW, Ferraro TN, et al. Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. Addict Biol 2006; 11:76-83.
18. Mossner R, Freitag CM, Gutknecht L, Reif A, Tauber R, Franke P, et al. The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. J Psychopharmacol 2006; 20:547-552.
19. Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005; 45:11-16.
20. Bicalho MA, Pimenta GJ, Neves FS, Correa H, de Moraes EN, De Marco L, et al. Genotyping of the G1463A (Arg441His) TPH2 polymorphism in a geriatric population of patients with major depression. Mol Psychiatry 2006; 11:799-800.
21. Blakely RD. Overview: a rare opportunity or just one less reason to be depressed. Neuron 2005; 48:701-702; author reply 705-706.
22. Delorme R, Durand CM, Betancur C, Wagner M, Ruhrmann S, Grabe HJ, et al. No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. Biol Psychiatry 2006; 60:202-203.
23. Garriock HA, Allen JJ, Delgado P, Nahaz Z, Kling MA, Carpenter L, et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005; 10:976-977.
24. Glatt CE, Carlson E, Taylor TR, Risch N, Reus VI, Schaefer CA. Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005; 48:704-705; author reply 705-706.
25. Van Den Bogaert A, De Zutter S, Heyrman L, Mendlewicz J, Adolfsson R, Van Broeckhoven C, et al. Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major Depression. Neuron 45, 11-16. Neuron 2005; 48:704; author reply 705-706.
26. Zhou Z, Peters EJ, Hamilton SP, McMahon F, Thomas C, McGrath PJ, et al. Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005; 48:702-703; author reply 705-706.
27. Breidenthal SE, White DJ, Glatt CE. Identification of genetic variants in the neuronal form of tryptophan hydroxylase (TPH2). Psychiatr Genet 2004; 14:69-72.
28. Lim JE, Pinsonneault J, Sadee W, Saffen D. Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry 2007; 12:491-501.
29. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62 (suppl 16):10-17.
30. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473.
31. Cervo L, Canetta A, Calcagno E, Burbassi S, Sacchetti G, Caccia S, et al. Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression. J Neurosci 2005; 25:8165-8172.
32. Crowley JJ, Blendy JA, Lucki I. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berlin) 2005; 183:257-264.
33. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berlin) 2001; 155:315-322.
34. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 2007; 7: 48-55.
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20):22-33; quiz 34-57.
36. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3:5-43.
37. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
38. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
39. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76:449-462.
40. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
41. Baldessarini R. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JL, Gilman AG, editors. Goodman & Gilman's: the pharmacological basis of therapeutics. New York: McGraw-Hill Companies, Inc.; 2001. pp. 447-485.
42. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP. Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 2005; 112:1479-1485.
43. Licinio J, Wong ML. Pharmacogenomics in psychiatry: clinical issues to be considered. Mol Psychiatry 2005; 10:615.
44. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2007; 8 (suppl 2):90-100.
45. Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika 1991; 78:691-692.
46. Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D'Souza UM. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet 2007; 144:1070-1078.
47. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 2001; 79:1033-1038.
48. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114:975-979.
49. Mill J, Asherson P, Craig I, D'Souza UM. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005; 6:3.
50. Miller GM, Madras BK. Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002; 7:44-55.
51. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9:879-889.
52. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423-1428.
53. Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 2004; 29:1012-1018.
54. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005; 5:49-53.
55. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.
56. Ke L, Qi ZY, Ping Y, Ren CY. Effect of SNP at position 40237 in exon 7 of the TPH2 gene on susceptibility to suicide. Brain Res 2006; 1122:24-26.
57. Lin YM, Chao SC, Chen TM, Lai TJ, Chen JS, Sun HS. Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Arch Gen Psychiatry 2007; 64:1015-1024.
58. Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P, et al. Characterization of a Functional Promoter Polymorphism of the Human Tryptophan Hydroxylase 2 Gene in Serotonergic Raphe Neurons. Biol Psychiatry 2007; 62:1288-1294.